![topcat trial topcat trial](https://onlinelibrary.wiley.com/cms/asset/fab684bb-f5f2-4a67-92c1-97ea87f11773/ejhf814-fig-0001-m.jpg)
Sites in Russia and the Republic of Georgia provided the majority of early enrollment, primarily based on the hospitalization criterion since BNP levels were initially unavailable there. Patients with a heart failure hospitalization in the last 12 months or an elevated B-type natriuretic peptide (BNP) were randomized to the mineralocorticoid receptor antagonist spironolactone vs.
![topcat trial topcat trial](https://www.frontiersin.org/files/Articles/707162/fcvm-08-707162-HTML-r1/image_m/fcvm-08-707162-g001.jpg)
#TOPCAT TRIAL TRIAL#
between treatment groups are found among different subgroups within a multicentre trial.TOPCAT was a multinational clinical trial of 3,445 heart failure with preserved ejection fraction (HFpEF) patients that enrolled in 233 sites in six countries in North America, Eastern Europe and South America. Despite the burden of this condition, no ventricular ejection fraction treatment tested in a clinical outcome trial has convincingly been 6– 8 At times, significant interactions (statistically significant differences) shown to improve outcomes in HFpEF. These patients share impaired quality of life and to geographic region and left poor prognosis with their HF counterparts with reduced ejection 4,5 fraction (HRrEF). European Journal of Heart Failure Wiley Įuropean Journal of Heart Failure (2016) 18, 1411–1414 VIEWPOINT doi:10.1002/ejhf.621 A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis 1 1,2 1 1 Nicolas Girerd, João Pedro Ferreira, Patrick Rossignol, and Faiez Zannad * INSERM, Centre d’Investigations Cliniques Plurithématique 1433, INSERM U1116, Université de Lorraine, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France and Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal Introduction Treatment interaction in TOPCAT: differences Heart failure with preserved ejection fraction (HFpEF) affects a large proportion of patients with the clinical syndrome of heart in treatment effect according 1– 3 failure (HF). Several post-hoc analyses of the TOP- CAT trial have been between treatment groups are found among different subgroups within a multicentre trial.
![topcat trial topcat trial](https://slideplayer.com/slide/17691172/105/images/23/TOPCAT%3A+Effects+of+Spironolactone+According+to+LVEF.jpg)
Girerd, Nicolas Ferreira, João Pedro Rossignol, Patrick Zannad, FaiezĮuropean Journal of Heart Failure (2016) 18, 1411–1414 VIEWPOINT doi:10.1002/ejhf.621 A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis 1 1,2 1 1 Nicolas Girerd, João Pedro Ferreira, Patrick Rossignol, and Faiez Zannad * INSERM, Centre d’Investigations Cliniques Plurithématique 1433, INSERM U1116, Université de Lorraine, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France and Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal Introduction Treatment interaction in TOPCAT: differences Heart failure with preserved ejection fraction (HFpEF) affects a large proportion of patients with the clinical syndrome of heart in treatment effect according 1– 3 failure (HF). A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain.